Zacks Research Has Negative Estimate for CRL Q3 Earnings

Key Points

• Zacks Research has revised down its Q3 2025 EPS estimate for Charles River Laboratories to $2.31, down from $2.35, impacting their overall earnings forecast.
• The medical research company has a current consensus estimate of $9.36 per share for the full year 2025, with additional earnings estimates showing a growth in upcoming quarters.
• Following a strong Q2 earnings report, where CRL exceeded expectations, several brokerages have adjusted their ratings and target prices, with most analysts maintaining a Hold rating overall.

Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) - Investment analysts at Zacks Research dropped their Q3 2025 earnings estimates for Charles River Laboratories International in a report released on Wednesday, August 27th. Zacks Research analyst Team now forecasts that the medical research company will post earnings of $2.31 per share for the quarter, down from their prior forecast of $2.35. The consensus estimate for Charles River Laboratories International's current full-year earnings is $9.36 per share. Zacks Research also issued estimates for Charles River Laboratories International's Q4 2025 earnings at $2.34 EPS, FY2025 earnings at $10.10 EPS, Q1 2026 earnings at $2.56 EPS and Q2 2026 earnings at $2.70 EPS.

A number of other research firms also recently commented on CRL. JPMorgan Chase & Co. upped their price objective on Charles River Laboratories International from $145.00 to $160.00 and gave the stock a "neutral" rating in a report on Thursday, August 7th. Citigroup upgraded Charles River Laboratories International from a "neutral" rating to a "buy" rating and upped their price objective for the stock from $150.00 to $200.00 in a report on Wednesday, July 9th. Evercore ISI upped their price objective on Charles River Laboratories International from $180.00 to $190.00 and gave the stock an "outperform" rating in a report on Friday, August 8th. TD Cowen upgraded Charles River Laboratories International from a "hold" rating to a "buy" rating and set a $179.00 price objective for the company in a report on Wednesday, May 14th. Finally, Wall Street Zen downgraded shares of Charles River Laboratories International from a "strong-buy" rating to a "buy" rating in a research note on Sunday, August 17th. Five equities research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of "Hold" and an average price target of $175.69.

Charles River Laboratories International Trading Up 1.0%

Shares of CRL stock traded up $1.69 on Monday, reaching $164.00. 598,963 shares of the stock were exchanged, compared to its average volume of 775,011. The stock has a market cap of $8.07 billion, a P/E ratio of -123.31, a price-to-earnings-growth ratio of 5.19 and a beta of 1.47. The company has a quick ratio of 1.10, a current ratio of 1.36 and a debt-to-equity ratio of 0.69. The firm has a 50 day moving average of $160.62 and a two-hundred day moving average of $149.14. Charles River Laboratories International has a 1-year low of $91.86 and a 1-year high of $230.02.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, August 6th. The medical research company reported $3.12 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.62. Charles River Laboratories International had a negative net margin of 1.69% and a positive return on equity of 15.74%. The firm had revenue of $1.03 billion during the quarter, compared to the consensus estimate of $983.76 million. During the same period in the previous year, the firm earned $2.80 earnings per share. Charles River Laboratories International's revenue was up .6% compared to the same quarter last year.

Insider Transactions at Charles River Laboratories International

In other Charles River Laboratories International news, EVP Joseph W. Laplume sold 800 shares of the business's stock in a transaction that occurred on Monday, August 18th. The shares were sold at an average price of $157.60, for a total transaction of $126,080.00. Following the completion of the sale, the executive vice president directly owned 24,116 shares in the company, valued at $3,800,681.60. The trade was a 3.21% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. 1.30% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in the company. Wellington Management Group LLP lifted its position in shares of Charles River Laboratories International by 5.1% during the first quarter. Wellington Management Group LLP now owns 4,285,012 shares of the medical research company's stock worth $644,980,000 after purchasing an additional 208,586 shares in the last quarter. Allspring Global Investments Holdings LLC boosted its position in Charles River Laboratories International by 29.1% in the 2nd quarter. Allspring Global Investments Holdings LLC now owns 2,291,126 shares of the medical research company's stock valued at $353,750,000 after buying an additional 516,521 shares during the last quarter. Kayne Anderson Rudnick Investment Management LLC boosted its position in Charles River Laboratories International by 8.0% in the 1st quarter. Kayne Anderson Rudnick Investment Management LLC now owns 1,950,273 shares of the medical research company's stock valued at $293,555,000 after buying an additional 144,732 shares during the last quarter. Ariel Investments LLC boosted its position in Charles River Laboratories International by 28.6% in the 2nd quarter. Ariel Investments LLC now owns 1,415,348 shares of the medical research company's stock valued at $214,751,000 after buying an additional 314,572 shares during the last quarter. Finally, Invesco Ltd. boosted its position in Charles River Laboratories International by 11.6% in the 2nd quarter. Invesco Ltd. now owns 1,237,143 shares of the medical research company's stock valued at $187,712,000 after buying an additional 128,785 shares during the last quarter. 98.91% of the stock is owned by institutional investors and hedge funds.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).